modelPhenylephrine
Extends from Pharmacolibrary.Drugs.ATC.S.S01FB01.
Information
| name: | Phenylephrine | |
| ATC code: | S01FB01 | route: | ophthalmic |
| compartments: | 1 | |
| dosage: | 10 | mg |
| volume of distribution: | 3.5 | L |
| clearance: | 24 | L/h/kg |
| other parameters in model implementation | ||
Phenylephrine is a selective alpha-1 adrenergic receptor agonist used as a decongestant, to increase blood pressure in hypotensive states, and as a mydriatic agent for ophthalmic use. In ophthalmology (ATC code S01FB01), it is topically applied to dilate the pupil for diagnostic or surgical procedures. It is approved and widely used in clinical practice.
Pharmacokinetics
Pharmacokinetic parameters for phenylephrine following topical ophthalmic administration in healthy adult volunteers.
References
Atkinson, HC, et al., & Anderson, BJ (2015). Potential cardiovascular adverse events when phenylephrine is combined with paracetamol: simulation and narrative review. European journal of clinical pharmacology 71(8) 931–938. DOI:10.1007/s00228-015-1876-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26022219
Seliniotaki, AK, et al., & Mataftsi, A (2022). Efficacy and safety of Mydriatic Microdrops for Retinopathy Of Prematurity Screening (MyMiROPS): study protocol for a non-inferiority crossover randomized controlled trial. Trials 23(1) 322–None. DOI:10.1186/s13063-022-06243-7 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35428316
Wang, ES, & Hammarlund, ER (1970). Corneal absorption reinforcement of certain mydriatics. Journal of pharmaceutical sciences 59(11) 1559–1563. DOI:10.1002/jps.2600591103 PUBMED:https://pubmed.ncbi.nlm.nih.gov/5495477
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)